Rapid test to assess the escape of SARS-CoV-2 variants of concern

Jacob T. Heggestad; Rhett J. Britton; David S. Kinnamon; Simone A. Wall; Daniel Y. Joh; Angus M. Hucknall; Lyra B. Olson; Jack G. Anderson; Anna Mazur; Cameron R. Wolfe; Thomas H. Oguin; Bruce A. Sullenger; Thomas W. Burke; Bryan D. Kraft; Gregory D. Sempowski; Christopher W. Woods; Ashutosh Chilkoti

doi:10.1126/sciadv.abl7682

Rapid test to assess the escape of SARS-CoV-2 variants of concern

Jacob T. Heggestad, Rhett J. Britton, David S. Kinnamon, Simone A. Wall, Daniel Y. Joh, Angus M. Hucknall, Lyra B. Olson, Jack G. Anderson, Anna Mazur, Cameron R. Wolfe, Thomas H. Oguin, Bruce A. Sullenger, Thomas W. Burke, Bryan D. Kraft, Gregory D. Sempowski, Christopher W. Woods, Ashutosh Chilkoti

Division of Pulmonary & Critical Care Medicine

Research output: Contribution to journal › Article › peer-review

20 Scopus citations

Abstract

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variants are concerning in the ongoing coronavirus disease 2019 (COVID-19) pandemic. Here, we developed a rapid test, termed CoVariant-SCAN, that detects neutralizing antibodies (nAbs) capable of blocking interactions between the angiotensin-converting enzyme 2 receptor and the spike protein of wild-type (WT) SARS-CoV-2 and three other variants: B.1.1.7, B.1.351, and P.1. Using CoVariant-SCAN, we assessed neutralization/blocking of monoclonal antibodies and plasma from COVID-19–positive and vaccinated individuals. For several monoclonal antibodies and most plasma samples, neutralization against B.1.351 and P.1 variants is diminished relative to WT, while B.1.1.7 is largely cross-neutralized. We also showed that we can rapidly adapt the platform to detect nAbs against an additional variant—B.1.617.2 (Delta)—without reengineering or reoptimizing the assay. Results using CoVariant-SCAN are consistent with live virus neutralization assays and demonstrate that this easy-to-deploy test could be used to rapidly assess nAb response against multiple SARS-CoV-2 variants.

Original language	English
Article number	eabl7682
Journal	Science Advances
Volume	7
Issue number	49
DOIs	https://doi.org/10.1126/sciadv.abl7682
State	Published - Dec 2021

Access to Document

10.1126/sciadv.abl7682

Cite this

Heggestad, J. T., Britton, R. J., Kinnamon, D. S., Wall, S. A., Joh, D. Y., Hucknall, A. M., Olson, L. B., Anderson, J. G., Mazur, A., Wolfe, C. R., Oguin, T. H., Sullenger, B. A., Burke, T. W., Kraft, B. D., Sempowski, G. D., Woods, C. W., & Chilkoti, A. (2021). Rapid test to assess the escape of SARS-CoV-2 variants of concern. Science Advances, 7(49), Article eabl7682. https://doi.org/10.1126/sciadv.abl7682

@article{2d16759111b24740b2b24ebc61f074f2,

title = "Rapid test to assess the escape of SARS-CoV-2 variants of concern",

abstract = "Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variants are concerning in the ongoing coronavirus disease 2019 (COVID-19) pandemic. Here, we developed a rapid test, termed CoVariant-SCAN, that detects neutralizing antibodies (nAbs) capable of blocking interactions between the angiotensin-converting enzyme 2 receptor and the spike protein of wild-type (WT) SARS-CoV-2 and three other variants: B.1.1.7, B.1.351, and P.1. Using CoVariant-SCAN, we assessed neutralization/blocking of monoclonal antibodies and plasma from COVID-19–positive and vaccinated individuals. For several monoclonal antibodies and most plasma samples, neutralization against B.1.351 and P.1 variants is diminished relative to WT, while B.1.1.7 is largely cross-neutralized. We also showed that we can rapidly adapt the platform to detect nAbs against an additional variant—B.1.617.2 (Delta)—without reengineering or reoptimizing the assay. Results using CoVariant-SCAN are consistent with live virus neutralization assays and demonstrate that this easy-to-deploy test could be used to rapidly assess nAb response against multiple SARS-CoV-2 variants.",

author = "Heggestad, {Jacob T.} and Britton, {Rhett J.} and Kinnamon, {David S.} and Wall, {Simone A.} and Joh, {Daniel Y.} and Hucknall, {Angus M.} and Olson, {Lyra B.} and Anderson, {Jack G.} and Anna Mazur and Wolfe, {Cameron R.} and Oguin, {Thomas H.} and Sullenger, {Bruce A.} and Burke, {Thomas W.} and Kraft, {Bryan D.} and Sempowski, {Gregory D.} and Woods, {Christopher W.} and Ashutosh Chilkoti",

note = "Publisher Copyright: Copyright {\textcopyright} 2021 The Authors, some rights reserved;",

year = "2021",

month = dec,

doi = "10.1126/sciadv.abl7682",

language = "English",

volume = "7",

journal = "Science Advances",

issn = "2375-2548",

number = "49",

}

TY - JOUR

T1 - Rapid test to assess the escape of SARS-CoV-2 variants of concern

AU - Heggestad, Jacob T.

AU - Britton, Rhett J.

AU - Kinnamon, David S.

AU - Wall, Simone A.

AU - Joh, Daniel Y.

AU - Hucknall, Angus M.

AU - Olson, Lyra B.

AU - Anderson, Jack G.

AU - Mazur, Anna

AU - Wolfe, Cameron R.

AU - Oguin, Thomas H.

AU - Sullenger, Bruce A.

AU - Burke, Thomas W.

AU - Kraft, Bryan D.

AU - Sempowski, Gregory D.

AU - Woods, Christopher W.

AU - Chilkoti, Ashutosh

PY - 2021/12

Y1 - 2021/12

N2 - Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variants are concerning in the ongoing coronavirus disease 2019 (COVID-19) pandemic. Here, we developed a rapid test, termed CoVariant-SCAN, that detects neutralizing antibodies (nAbs) capable of blocking interactions between the angiotensin-converting enzyme 2 receptor and the spike protein of wild-type (WT) SARS-CoV-2 and three other variants: B.1.1.7, B.1.351, and P.1. Using CoVariant-SCAN, we assessed neutralization/blocking of monoclonal antibodies and plasma from COVID-19–positive and vaccinated individuals. For several monoclonal antibodies and most plasma samples, neutralization against B.1.351 and P.1 variants is diminished relative to WT, while B.1.1.7 is largely cross-neutralized. We also showed that we can rapidly adapt the platform to detect nAbs against an additional variant—B.1.617.2 (Delta)—without reengineering or reoptimizing the assay. Results using CoVariant-SCAN are consistent with live virus neutralization assays and demonstrate that this easy-to-deploy test could be used to rapidly assess nAb response against multiple SARS-CoV-2 variants.

AB - Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variants are concerning in the ongoing coronavirus disease 2019 (COVID-19) pandemic. Here, we developed a rapid test, termed CoVariant-SCAN, that detects neutralizing antibodies (nAbs) capable of blocking interactions between the angiotensin-converting enzyme 2 receptor and the spike protein of wild-type (WT) SARS-CoV-2 and three other variants: B.1.1.7, B.1.351, and P.1. Using CoVariant-SCAN, we assessed neutralization/blocking of monoclonal antibodies and plasma from COVID-19–positive and vaccinated individuals. For several monoclonal antibodies and most plasma samples, neutralization against B.1.351 and P.1 variants is diminished relative to WT, while B.1.1.7 is largely cross-neutralized. We also showed that we can rapidly adapt the platform to detect nAbs against an additional variant—B.1.617.2 (Delta)—without reengineering or reoptimizing the assay. Results using CoVariant-SCAN are consistent with live virus neutralization assays and demonstrate that this easy-to-deploy test could be used to rapidly assess nAb response against multiple SARS-CoV-2 variants.

UR - http://www.scopus.com/inward/record.url?scp=85120717754&partnerID=8YFLogxK

U2 - 10.1126/sciadv.abl7682

DO - 10.1126/sciadv.abl7682

M3 - Article

C2 - 34860546

AN - SCOPUS:85120717754

SN - 2375-2548

VL - 7

JO - Science Advances

JF - Science Advances

IS - 49

M1 - eabl7682

ER -

Rapid test to assess the escape of SARS-CoV-2 variants of concern

Abstract

Access to Document

Other files and links

Fingerprint

Cite this